Treatment of ErbB2 breast cancer by mitochondrial targeting

ConclusionsMitochondrial targeting by MEDICA suppresses ErbB2 breast tumors and metastasis due to lipid raft disruption and inhibition of mTORC1 activity. Inhibition of mTORC1 activity by MEDICA avoids the resistance acquired by canonical mTORC1 inhibitors like rapalogs or mTOR kinase inhibitors.

Source: Cancer and Metabolism - July 13, 2020 Category: Cancer & Oncology Source Type: research